Добавил:
kiopkiopkiop18@yandex.ru t.me/Prokururor I Вовсе не секретарь, но почту проверяю Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз: Предмет: Файл:
Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_837_Библиотеки_им_академика_М_И_Перельмана.pdf
Скачиваний:
0
Добавлен:
31.08.2026
Размер:
38 Мб
Скачать

Non-healing Perineal Wounds

JoshuaH.Wolf andMartinNewman
25
Refer toAlgorithm inFig. 25.1
A. Patient history should be directed toward
eliciting the various risk factors that have either prevented or arrested progression towards complete healing. Some of these fac­tors may be subject to modication, includ­ing tobacco abuse, alcohol addiction, nutritional deciency, and obesity. Inammation is a normal and important phase of wound healing, and medications that attenuate the inammatory process, such as steroids, immunosuppressive or anti-meta­bolic drugs may have a profound effect on wound progression. Modiable risks should be reduced or eliminated. Patients should be counseled regarding the importance of smok­ing cessation and weight loss, and total nutri­tional support should be considered in cases of chronic malnutrition.
B. Certain non-modiable attributes can also
predispose patients to NHPW. The largest study of perineal wounds after APR to date, by Althumari et al. (reference listed in
J. H. Wolf (*) Department of Surgery, Sinai Hospital, LifeBridge Health, Baltimore, MD, USA e-mail: wolfj3@ccf.org
M. Newman Department ofPlastic andReconstructive Surgery, Cleveland Clinic Florida, Weston, FL, USA
“Further Reading”), found that wound com­plications were associated with African American race, ASA class >4, smoking his­tory, obesity, and chronic obstructive pulmo­nary disease (COPD). Other comorbid conditions that have been associated with poor wound healing include diabetes, inam­matory bowel disease (IBD), immunode­ciency and vasculopathy. While these comorbidities are not generally reversible, they should be aggressively controlled with medical treatment and specialty consultation.
C. Cellular injury due to radionecrosis, burns or
pressure sores will signicantly impede heal­ing, and may ultimately lead to ulceration and necrosis. Radiation injury in the form of radionecrosis is unique in that the injury may be both delayed (6weeks after exposure) and then progressive over time. Pressure ulcer­ation in the perineum occurs in bedridden or paraplegic patients, and may rst compro­mise the tissue immediately overlying the ischium or sacrum. In many cases of cellular injury, tissue is scarred or malperfused in the areas surrounding the wound itself. This may limit the success of local rotational aps and skin grafts. Non-viable tissue should be widely debrided and reconstructed with tis­sue from outside the zone of injury, i.e. a regional or free ap.
© Springer Nature Switzerland AG 2020 S. R. Steele etal. (eds.), Clinical Decision Making in Colorectal Surgery,
https://doi.org/10.1007/978-3-319-65942-8_25
195
196
Fig. 25.1 Algorithm for management of non-healing perineal wounds
J. H. Wolf and M. Newman
D. Perineal surgery often overlaps with one or
several of the above risk factors. For exam­ple, abdominoperineal resection (APR) for rectal cancer may involve a radiated eld from neoadjuvant treatment. Perianal sur­gery or APR in the setting of Crohn’s disease can lead to scarring in an already malnour­ished patient on immunosuppressive ther­apy. The surgeon may wish to consider these additional factors when planning an opera­tive approach. For example, it may be pref­erable to delay proctectomy and perineal closure in patients with Crohn’s or mucosal ulcerative colitis and perform a staged pro­cedure. If appropriate, intersphincteric dis­section may help reduce wound size and improve closure integrity. Surgical position­ing should be carefully considered as well, as some data have suggested higher rates of wound failure for patients positioned in lithotomy.
E. Infection must be denitely controlled to
allow for wound closure. Fournier’s gan­grene is a polymicrobial necrotizing infec­tion requiring aggressive debridement, broad spectrum antibiotic coverage and frequent dressing changes with Betadine or saline soaked gauze. Repeat debridement is often required to remove all nonviable tissue.
Other infectious causes for NHPW include pilonidal disease and hidradenitis suppura­tiva, and management for both of these problems can be found in other chapters of this book.
F. NHPWs may also harbor malignancies in
two distinct scenarios: (1) If the perineal wound is related to an already known malig­nancy, for example, an APR that was per­formed for Nigro-resistant or recurrent squamous cell carcinoma, then any delayed healing should prompt a high index of suspi­cion for recurrent disease. (2) Malignant transformation can occur in the absence of cancer history, arising de novo in chronically inamed tissue. A rm plaque or fungating mass in a non-healing wound bed should raise suspicion and biopsy should be consid­ered. However, the specic steps for diagno­sis and treatment for soft tissue tumors of the perineum are beyond the scope of this chapter.
G. Physical examination of NHPW involves
careful assessment of the following wound features: (a) Dimensions. (b) Structures involved (e.g., bone, muscle,
soft tissue and skin).
(c) Anatomic position.
25 Non-healing Perineal Wounds
197
(d) Presence or absence of infection. (e) Quality of surrounding tissue. (f) Involvement of urogynecological or neu-
rologic structures.
Full evaluation requires a digital rectal examination in men and women, a vaginal and bimanual examination in women. There are often obstacles that prevent this from being done in the ofce, such as patient body habitus, pain and tenderness, need for multiple biopsies, or patient anxi­ety. In these scenarios the examination may be performed in the operating room under anesthesia at the discretion of the operating surgeon.
H. Imaging is not always critical, but it may
often be helpful to exclude underlying pro­cesses such as abscess, stulae, or bony involvement. Studies may include pelvic computed tomography (CT), magnetic reso­nance imaging (MRI), or stulagram. Bone scans can be used to assist with evaluation of osteomyelitis. However, bone biopsy is often required to conrm the diagnosis.
I. Macrodebridement and microdebridement
are two options for cleaning wounds in preparation for further healing and eventual closure. Macrodebridement involves surgi­cal excision of nonviable or infected tissue back to healthy-appearing bleeding edges, and removal of any brinous debris. Depending on the degree of involvement, this can be accomplished at the bedside or in the operating room under anesthesia. Microdebridement refers to the use of regu­lar wet-to-dry dressing changes, which help remove brin and stimulate growth of fresh granulation tissue.
J. Fecal diversion may be appropriate in cases
in which microdebridement or secondary healing will likely be impeded by contami­nation. Examples include complex perianal stulae (watering-can perineum), perineal wounds in patients with baseline fecal incon­tinence, or large or complex wounds imme­diately adjacent to the sphincter complex.
K. Urology/gynecology consultation can be
helpful when stulae to these respective organ systems have been demonstrated on physical examination or imaging.
L. Based on a variety of clinical, psychological
and social factors a course of healing by sec­ondary intention may prove the best options in some cases, for example, if the patient is a poor surgical candidate. Healing by secondary inten­sion may also be the appropriate choice for wounds that are too large for primary closure, or that contain persistent contamination requir­ing serial macrodebridement. It should be noted, however, that healing by secondary intention can be a very lengthy and labor inten­sive/resource fueled endeavor. Thus, a variety of adjuncts have been developed to expedite the process. Moist wound dressings include algi­nate, silicone or polyurethane foam or beads, or hydrocolloid dressings. There are mixed data regarding superior healing for any of these techniques over gauze dressings, though foam dressings have been shown to improve patient comfort. Antimicrobial applications such as Betadine, Medihoney, petroleum or silver sul­fasalazine are used to theoretically help reduce contamination. Negative- pressure wound dressings (NPWD) have been credited by many as helpful in promoting granulation and even­tual re- epithelialization. The data on hyperbaric oxygen therapy is mixed but leans towards hav­ing an overall benecial effect on wound healing in certain cases. Bioelectric treatments and stem cell-based therapies remain experimental.
M. Direct primary closure for NHPWs can be
attempted once the wound is clear of infec­tion and necrosis. Re-approximation is an option if there are healthy appearing skin edges that approximate without tension.
N. For deeper, more complex NHPWs that are
not amenable to direct re-approximation, ap closures can be considered. Flaps can be broadly categorized by proximity to the wound, and the strengths and weaknesses of each subtype are reviewed in Table25.1.
198
Table 25.1 Categorization of ap subtypes
Flap type Vascular pedicle Advantage Disadvantage
Local Random blood supply Avoids donor site
Regional
Gracilis Medial femoral
Gluteus maximus
Rectus abdominis
Omental Right or left
Free
Anterolateral thigh
circumex artery
Inferior or superior gluteal artery
Deep inferior epigastric artery
gastroepiploic artery
Descending branch of lateral femoral circumex artery
morbidities that accompany regional and free aps Simple to design and execute
Minimal functional morbidity, avoids abdominal incision
Minimal functional morbidity, avoids abdominal incision
Large tissue bulk Risk of incisional hernia at donor site,
Large tissue bulk Laparotomy or laparoscopic harvest
Minimal functional morbidity, avoids abdominal incision
Broad application restricted by limited bulk and need for excellent tissue quality surrounding wound
Small skin paddle and limited tissue bulk
Limited arc of rotation
obliteration of potential future stoma site
required, no skin paddle
Only moderate bulk Signicant anatomic variability Time consuming and technically demanding
J. H. Wolf and M. Newman
(a) Local aps generally refer to the transpo-
sition—in one form or another—of adja­cent skin and subcutaneous tissue into the wound bed and are based on—most often—a random blood supply. A rota­tional ap is a commonly employed example. Local aps are usually accept­able if the surrounding tissue is well per­fused, not scarred or brotic, and has not been exposed to radiation. Tissue must be easily transferable without tension. This type of ap differs signicantly from the others that will be discussed because the vascular pedicle is not spe­cically isolated.
(b) Regional aps are usually larger seg-
ments of tissue mobilized from their native tissue beds and imported to ll the defect in question. These aps may include a combination of skin, subcuta­neous tissue, fascia and muscle. However, pure muscle or simple fascio­cutaneous aps often are adequate.
Regional aps often involve careful preservation of the vascular pedicle. Thus, the native vessels supplying these aps must have adequate length to reach the wound. Common regional ap options include gracilis, gluteus maxi­mus, rectus abdominis myocutaneous aps or omental pedicle aps. Mobilization, transfer and nal position­ing of both a gracilis ap and vertical rectus abdominis myocutaneous ap (VRAM) are shown in Figs. 25.2 and
25.3, respectively.
(c) Free ap closure represents the top rung
of the reconstructive ladder. Although free aps are more technically demand­ing than the other options listed and are associated with signicant donor site morbidity, they are uniquely capable of lling defects when all other options have been exhausted, An common exam­ple of such is the anterolateral thigh fas­ciocutaneous ap.
ab
cd
ab
25 Non-healing Perineal Wounds
199
Fig. 25.2 Gracilis muscle ap harvest and transposition. The gracilis muscle is identied and mobilized through two incisions along medial thigh with care to preserve its vascular pedicle (a and b). It is then tunneled subcutane-
c
ously and transposed into the perineal defect (c). Final incisions are shown at case conclusion (d). (Courtesy of Dr. Steven D.Wexner)
Fig. 25.3 Vertical rectus abdominis myocutaneous ap (VRAM). The rectus abdominis muscle is mobilized with a skin paddle (a) and brought into the perineal wound (b).
The regional ap is perfused by the inferior epigastric artery. Final incisions and drain placement are shown at case conclusion (c). (Courtesy of Dr. Steven D.Wexner)
200
J. H. Wolf and M. Newman

Suggested Reading

Althumairi A, Canner JK, Gearhart S, Safar B, Fang S,
Wick EC, Efron JE.Risk factors for wound compli­cations after abdominoperineal excision: analysis of ACS NSQIP database. Color Dis. 2016;18:O260–6.
Boatent J, Catanzano O.Advanced therapeutic dressings
for effective wound healing—a review. J Pharm Sci. 2015;104:3653–80.
Genua JC, Vivas DA.Management of nonhealing perineal
wounds. Clin Colon Rectal Surg. 2007;20:322–8.
Kamrava A, Mahmoud NN. Prevention and management
of nonhealing perineal wounds. Clin Colon Rectal Surg. 2013;26:106–11.
Moon HK, Caminer D, Boyd JB. Chapter 42: unhealed
perineal wounds. In: Wexner SD, Vernava A, edi­tors. Clinical decision-making in colorectal surgery. Philadelphia: Lippincott and Williams; 1995.
Vermeulen H, Ubbink DT, Goossens VRD, Legemate
DA.Systematic review of dressings and topical agents for surgical wounds healing by secondary intention. British J Surgery. 2005;92:665–72.

Anal Intraepithelial Neoplasms

AlexisR.Harvey andScottR.Steele
26
Refer toAlgorithm in Fig.26.1
A. Carcinoma of the anus is a relatively rare
cancer, with an annual incidence less than 2/100,000, and the incidence has been rising at a rate of 2.2% each year, due largely to improved survival of persons with HIV.The National Cancer Institute estimates 8080 new cases and 1080 deaths will occur in
2016. Incidence is highest among white females and black men (2.1/100,000) and median age at presentation is 61years. Five­year mortality is 66.4% overall but 80.7% if discovered while still conned to the pri­mary site. According to the Centers for Disease Control, more than 90% of these malignancies are associated with human papillomavirus (HPV), primarily serotypes 16 and 18. Similar to HPV-related cervical cancers, anal cancer is preceded by a pro­tracted pre-malignant dysplastic phase called anal intraepithelial neoplasia (AIN), supporting a role for routine screening in high-risk populations and early, targeted treatment and/or active surveillance when dysplasia is recognized. Vaccination against
A. R. Harvey School ofMedicine, Case Western Reserve University, Cleveland, OH, USA
S. R. Steele (*) Department ofColorectal Surgery, Cleveland Clinic, Cleveland, OH, USA
oncogenic strains of HPV can prevent anal cancer. Vaccination is most effective when administered before risk of HPV exposure, but there is evidence that post-exposure vac­cination is also protective.
Risk factors for anal intraepithelial neo­plasms include HPV infection, HIV seroposi­tivity, history of anoreceptive intercourse, increased number of lifetime sexual partners, history of other HPV-related neoplasia (e.g., cervical intraepithelial neoplasia, cervical cancer), immunosuppression due to trans­plantation, and smoking. We recommend vac­cination and annual routine screening by anal Pap smear (refer to section B in algorithm) in this population. A thorough patient history is critical to elucidate relevant risk factors. HIV+ patients must be compliant with HAART to benet from HPV vaccination.
Routine screening is not recommended for persons not at increased risk but may be indi­cated based on clinical suspicion of AIN or anal cancer. In this population, normal cytol­ogy does not require additional follow up.
B. The anal Papanicolaou (Pap) smear is per-
formed in the same manner as a standard cervical Pap smear. Advise the patient to refrain from anoreceptive intercourse and intra-anal enema or other preparation prior to examination. A small brush or Dacron swab moistened with water is inserted into the anus 2–3 in beyond the internal anal
© Springer Nature Switzerland AG 2020 S. R. Steele etal. (eds.), Clinical Decision Making in Colorectal Surgery,
https://doi.org/10.1007/978-3-319-65942-8_26
201
202
A. R. Harvey and S. R. Steele
Fig. 26.1 Algorithm for treatment of anal intraepithelial neoplasms
sphincter and dentate line. Using rm lateral pressure, continuously rotate the swab 360° while withdrawing slowly from the anus. Sample collection should take 15–30 s, being sure to sample the entire anal canal, including the non-keratinized mucosa, the anorectal junction, and the keratinized anal verge. Fix and package the sample for trans­port according to the test manufacturer’s specications. Do not use a cotton swab or lubrication as they will interfere with the slide mount and interpretation. Deliver to a trained pathologist for interpretation. As part of a thorough physical examination, a digital rectal exam (DRE) should be per­formed to detect frank lesions.
Normal ndings in high-risk individuals with no visually-apparent lesion or concern­ing symptoms (anal itching, bleeding, and/or pain) are referred for repeat screening in 1 year. Normal ndings in persons not at
increased risk do not require additional fol­low- up. Atypical results, regardless of risk factors, are referred for high resolution anos­copy (refer to section C in algorithm).
C. High-resolution anoscopy is used to visual
dysplasia invivo. Acetic acid (3%) turns ace­towhite when applied to dysplastic tissue. Using an anoscope to access the anal canal, a gauze-wrapped cotton swabbed dipped in 3% acetic acid is placed in the canal and the anoscope is removed. After 1 min, the ano­scope is reinserted and the cotton swab gen­tly removed. A colposcope is used to magnify and thoroughly inspect the anal canal. If no lesion is found, the patient should be re­examined periodically (refer to section D in the algorithm). Dysplastic tissue that has turned white can be further investigated by applying Lugol’s solution. Lesions that do not take up Lugol’s solution are more likely to be a high-grade dysplasia. Reactive tissue
26 Anal Intraepithelial Neoplasms
203
should be biopsied for diagnosis (refer to section E in algorithm). As part of a thorough physical examination, a digital rectal exam should be performed to detect frank lesions.
D. Active surveillance simply means serial
examinations with high resolution anoscopy at regular periods to discover new lesions in at-risk individuals; to monitor changes in slow-growing lesions; or to catch recurrence in treated individuals. HPV is notoriously persistent because the virus can lie dormant in seemingly uninvolved tissue or be re­introduced in an individual that has fully cleared their infection. Furthermore, infec­tion with one strain does not confer immunity against other strains.
• Atypical cytology (section B) suggests
exposure and/or increased risk even if a
frank lesion is not apparent (section C).
These patients should be re-examined by
DRE and HRA every 3–6months for sev-
eral years (varies by institutional prac-
tices) prior to going back to the screening
regimen once stable and free of disease.
• Medically managed non-cancerous lesions
require monitoring every 3–6 months to
assess response to treatment or progression
to a higher-grade lesion or to cancer.
Monitoring should continue as long as dys-
plasia is appreciated, even if it is respond-
ing to treatment. Persistent or progressive
lesions may require ablation. If lesion
regresses, monitoring should continue
every 3–6months for recurrence as above.
• High-grade lesions treated with ablation
require active surveillance every
3–6months for recurrence.
• Cancers treated with chemoradiation or
surgical resection require active surveillance
every 3–6months to look for persistence or
recurrence in accordance with NCCN and
ASCRS clinical practice guidelines.
E. Lesions discovered during HRA can be
immediately biopsied using forceps and a scalpel. The small sample should be formalin xed and sent to a pathologist for evaluation.

Diagnoses

F. Condylomata are epidermal growths caused
by one of more than 30 distinct strains of HPV, though 90% are caused by strains 6 and
11. These strains are very unlikely to cause cancer, but history of condylomata is associ­ated with exposure to other, some oncogenic, strains of HPV and potentially the develop­ment of cancer. All persons presenting with HPV condylomata can be treated with a topi­cal agent or targeted destruction. They should also be offered vaccination to protect against future re-infection. High-risk individuals should continue annual screening for neoplasia.
Topical treatments include 5% imiquimod cream and 5% 5-uorouracil (FU) cream. Imiquimod is an immune modulator that acts to stimulate the body’s natural immune sys­tem against the HPV infection. The cream is applied at bedtime three times per week for up to 16weeks and washed off with soap and water the next morning. Imiquimod is not always curative, and may cause side effects— redness, irritation, induration, or ulceration— that are sometimes bothersome enough to affect patient compliance. Topical 5-FU blocks DNA replication, preventing a cell population from continuing to grow. It is used for 9–16 weeks with very good response rates. Targeted tissue destruction (ablation) using HRA-guided infrared coagulation may also be used. There is a high risk of recur­rence with all of these treatments, further supporting the recommendation that high­risk individuals continue annual screening.
G. Anal intraepithelial neoplasia I (AIN I) is low-
grade dysplasia and is believed to be caused by a transient, self-limited HPV infection that has a low chance of progressing to cancer. There have been several categorization schemes dened to characterize anal neopla­sia. AIN I is synonymous with the early cyto­logical designation of low-grade squamous intraepithelial lesion (LSIL) and the WHO’s
204
A. R. Harvey and S. R. Steele
classication of low-grade anal intraepithelial neoplasia (LGAIN). Despite the adoption of screening practices, AIN I is often discovered incidentally during an unrelated procedure. Note that AIN and cervical intraepithelial neo­plasia often occur simultaneously, so women diagnosed should also be referred to a gyne­cologist for a thorough examination.
AIN I is unlikely to progress to malig­nancy, especially in immunocompetent patients and those not engaged in high risk behaviors; although the chance of progres­sion is higher in immunosuppressed patients. These slow-growing lesions are best treated with topical agents and followed closely in active surveillance. Because of the risk of recurrence or re-infection, vaccination should be offered to these high-risk patients.
In persons who are not at increased risk, topical therapy and active surveillance (i.e., “watch and wait”) may be used or they may opt for targeted ablation and then follow up with an annual screening Pap smear.
H. Anal intraepithelial neoplasia II and III, inter-
mediate- and high-grade neoplasia, are con­sidered together. These designations are synonymous with high-grade squamous intraepithelial lesion and high-grade anal intraepithelial neoplasia. These lesions tend to be more persistent, more aggressive, and more likely to progress to malignancy. Treatment of them is only slightly more aggressive, however. High-risk individuals may choose the topical or targeted ablation with active surveillance. Those not at increased risk should be treated with ablation and also followed in active surveillance. Recurrence or persistence and progression are not uncommon in this group, so continued surveillance is critical.
I. Anal cancers may be of several histologic
types, including cloacogenic, basaloid, epi­dermoid, and mucoepidermoid, but the major­ity are squamous cell carcinomas. While they together represent less than 2% of all colorec­tal malignancies, incidence is increasing and morbidity is high.
Anal cancers develop as a slow-growing
mass within the anal canal as far as the anorec-
tal junction, at the anal verge, or in the peri­anal region. Symptoms are present in 50% of cases and may include pain, bleeding, pruri­tus, irritation; 20% of cases are asymptomatic at presentation. Half of anal cancer patients present with localized disease, one-third with regional nodal involvement, and 10–15% with distant metastases. Most commonly involved lymph nodes are the inguino-femoral group and may cause groin pain.
A cancer diagnosis should prompt a com­plete physical exam including visual inspec­tion, digital rectal exam, and lymph node investigation to conrm the disease and determine stage. The digital rectal exam can reveal location, xation, and/or invasion. Palpate the groin for lymphadenopathy; per­form a ne needle biopsy on suspicious nodes. Anoscopic or sigmoidoscopic biopsy may facilitate staging and enable assessment for concomitant colorectal neoplasms. A CT of the chest, abdomen, or pelvis should be ordered to evaluate lymph node involvement and regional spread. Consider a PET/CT if distant metastases are suspected. Stage according to the American Joint Committee on Cancer (AJCC) small cell cancer (SCC) staging criteria.
Local disease (conned to the primary site) and regional disease (lymph node involvement) are both treated with standard CRT and then followed with active surveil­lance as described below. Standard CRT includes mitomycin C (MMC) and 5-uoro­uracil (5-FU) plus gamma radiation of the pelvic basin from L5/S1 to the perianal skin, including pelvic and inguino- femoral lymph nodes in the eld.
Regional disease requires that the radiation eld be expanded to include the area around he involved lymph node. Studies have shown that CRT has equivalent outcomes to the pre­vious standard treatment—abdominoperineal resection (APR)—while preserving the sphincter function for the patient. Radiation alone is not recommended.
Cancer located at the anal margins present with bleeding, pruritus, and an ulcerated mass with rolled, everted edges. They are staged